Bortezomib in the treatment of mantle cell lymphoma

Future Oncology
Tadeusz Robak

Abstract

Mantle cell lymphoma (MCL) is a hematological malignancy with unfavorable prognosis. Bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, was shown to be active in MCL and is currently implemented in therapeutic combinations. Single-agent bortezomib has demonstrated clinical efficacy in relapsed and refractory MCL with objective response in up to 47% of the patients. However, complete remission rates are low and duration of response is relatively short. In previously untreated patients, the addition of bortezomib to induction chemotherapy is also promising. Further evaluation of bortezomib alone or in combination with other drugs for the treatment of MCL is warranted to improve the quality of life and survival of patients. This review explores bortezomib as therapy in patients with MCL.

References

Jun 22, 2000·American Journal of Hematology·D D WeisenburgerJ O Armitage
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Orion M HowardMargaret A Shipp
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Nicholas MitsiadesKenneth C Anderson
Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lan V PhamRichard J Ford
Dec 12, 2003·Annals of Hematology·G LenzW Hiddemann
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyAlma M Rodriguez
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorAndrew D Zelenetz
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E Witzig
Apr 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra J StraussT Andrew Lister
Sep 15, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BelchE A Eisenhauer
Sep 27, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherAndré Goy
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert C KaneRichard Pazdur
Dec 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoyR I Fisher
Nov 19, 2009·British Journal of Haematology·Enrico OrciuoloMario Petrini
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jia RuanJohn P Leonard
Jun 11, 2011·Critical Reviews in Oncology/hematology·Sergio CortelazzoMartin Dreyling
Jun 30, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marc A WenigerAdrian Wiestner
Jun 20, 2012·Cancer Control : Journal of the Moffitt Cancer Center·Bijal D ShahEduardo M Sotomayor
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Sep 12, 2012·American Journal of Hematology·Hyun Joo JungNami McCarty
Mar 21, 2013·Current Treatment Options in Oncology·L Kyle Brett, Michael E Williams
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitchell R Smith
Apr 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eva HosterMichael Unterhalt
May 27, 2014·American Society of Clinical Oncology Educational Book·Martin Dreyling, UNKNOWN European Mantle Cell Lymphoma Network

❮ Previous
Next ❯

Citations

Apr 28, 2016·Pharmacological Reports : PR·Krzysztof OlesJoanna Mika
Oct 25, 2016·Nature Communications·Anita SchlierfBruno Martoglio
Apr 26, 2019·Leukemia & Lymphoma·Tadeusz RobakMartin Dreyling
Jan 3, 2020·JAMA Otolaryngology-- Head & Neck Surgery·Ibrahim AbukhiranSergei Syrbu
Apr 18, 2019·Drugs in R&D·Pawel Robak, Tadeusz Robak
Mar 9, 2020·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Wenxiao JiangXueqiong Zhu

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01449344
NCT00114738

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.